Search for Clinical Trial Results

Sponsored By

Hemoglobinuria, Paroxysmal - 8 Studies Found

Status Study
Completed Study Name: Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Condition:
  • Aplastic Anemia
  • Paroxysmal Hemoglobinuria, Nocturnal

Date: 1999-10-18
Interventions:
  • Drug: cyclophosphamide
  • Drug: filgrastim
Completed Study Name: Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
Condition:
  • Hematologic Neoplasms
  • Anemia, Aplastic
  • Myeloid Malignancy
  • Inherited Bone Marrow Failure Syndrome

  • Date: 2016-11-04
    Interventions: Other: follow up
Enrolling by invitation Study Name: The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population
Condition: Bone Marrow Failure Syndrome
Date: 2015-03-05
Interventions:
  • Other: Fresh Human Red Blood Cells

Enrolling by invitation Study Name: Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
Condition:
  • Hematological Malignancy
  • Bone Marrow Failure Syndrome

Date: 2012-12-06
Interventions: Drug: Eltrombopag From day +1, start eltrombopag 100 mg/d.
Active, not recruiting Study Name: Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device
Condition:
  • Malignant Diseases (ie, Leukemia, MDS, Lymphoma)
  • Non-malignant Diseases (ie, Bone Marrow Fai
    Date: 2010-02-17
    Interventions:
    • Device: CliniMACS (CD+3, CD+19 depletion)

Recruiting Study Name: Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date: 2017-03-08
Interventions: Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d
Recruiting Study Name: Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date: 2017-01-20
Interventions: Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d